BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33259676)

  • 1. Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Banga Ndzouboukou JL; Lei Q; Ullah N; Zhang Y; Hao L; Fan X
    Helicobacter; 2021 Feb; 26(1):e12758. PubMed ID: 33259676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils.
    Guo L; Yin R; Xu G; Gong X; Chang Z; Hong D; Liu H; Ding S; Han X; Li Y; Tang F; Liu K
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28851031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against Helicobacter pylori infection by a trivalent fusion vaccine based on a fragment of urease B-UreB414.
    Wang L; Liu XF; Yun S; Yuan XP; Mao XH; Wu C; Zhang WJ; Liu KY; Guo G; Lu DS; Tong WD; Wen AD; Zou QM
    J Microbiol; 2010 Apr; 48(2):223-8. PubMed ID: 20437155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection.
    Keikha M; Eslami M; Yousefi B; Ghasemian A; Karbalaei M
    J Cell Physiol; 2019 Dec; 234(12):21460-21470. PubMed ID: 31188484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on
    Guo L; Yang H; Tang F; Yin R; Liu H; Gong X; Wei J; Zhang Y; Xu G; Liu K
    Front Cell Infect Microbiol; 2017; 7():349. PubMed ID: 28824883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the crystal structure of the HpaA adhesin: insights into cell adhesion function and epitope localization of a
    Martini C; Araba V; Beniani M; Armoa Ortiz P; Simmons M; Chalbi M; Mellouk A; El Bakkouri M; Calmettes C
    mBio; 2024 Mar; 15(3):e0295223. PubMed ID: 38376163
    [No Abstract]   [Full Text] [Related]  

  • 7. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori.
    Flach CF; Svensson N; Blomquist M; Ekman A; Raghavan S; Holmgren J
    Vaccine; 2011 Feb; 29(6):1235-41. PubMed ID: 21147129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses.
    Nyström J; Svennerholm AM
    Vaccine; 2007 Mar; 25(14):2591-8. PubMed ID: 17239498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: An in silico approach.
    Meza B; Ascencio F; Sierra-Beltrán AP; Torres J; Angulo C
    Infect Genet Evol; 2017 Apr; 49():309-317. PubMed ID: 28185986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice.
    Huang X; Xu B; Duan G; Song C
    Curr Microbiol; 2013 Oct; 67(4):487-92. PubMed ID: 23715666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed enterotoxigenic Escherichia coli fimbrial antigens.
    Tobias J; Lebens M; Wai SN; Holmgren J; Svennerholm AM
    Microb Pathog; 2017 Apr; 105():177-184. PubMed ID: 28215587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design of vaccines against Helicobacter pylori and their development.
    Del Giudice G; Covacci A; Telford JL; Montecucco C; Rappuoli R
    Annu Rev Immunol; 2001; 19():523-63. PubMed ID: 11244046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination.
    Prinz C; Hafsi N; Voland P
    Trends Microbiol; 2003 Mar; 11(3):134-8. PubMed ID: 12648945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background.
    Sutton P; Doidge C; Pinczower G; Wilson J; Harbour S; Swierczak A; Lee A
    FEMS Immunol Med Microbiol; 2007 Jul; 50(2):213-9. PubMed ID: 17567282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of vaccines against Helicobacter pylori.
    Del Giudice G; Malfertheiner P; Rappuoli R
    Expert Rev Vaccines; 2009 Aug; 8(8):1037-49. PubMed ID: 19627186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation.
    Prinz C; Schöniger M; Rad R; Becker I; Keiditsch E; Wagenpfeil S; Classen M; Rösch T; Schepp W; Gerhard M
    Cancer Res; 2001 Mar; 61(5):1903-9. PubMed ID: 11280745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of Helicobacter pylori and perspectives of vaccine development against an emerging pathogen.
    Rappuoli R; Covacci A; Ghiara P; Telford J
    Behring Inst Mitt; 1994 Dec; (95):42-8. PubMed ID: 7755508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies.
    Tang RX; Luo DJ; Sun AH; Yan J
    World J Gastroenterol; 2008 Aug; 14(30):4816-22. PubMed ID: 18720546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Protection Against
    Guo L; Hong D; Wang S; Zhang F; Tang F; Wu T; Chu Y; Liu H; He M; Yang H; Yin R; Liu K
    Front Immunol; 2019; 10():1185. PubMed ID: 31191547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A vaccine against Helicobacter pylori infection].
    Presecki V; Katicić M; Kalenić S; Strnad M; Plecko V; Babus V; Dominis M
    Lijec Vjesn; 2002 Sep; 124 Suppl 1():79-82. PubMed ID: 12592824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.